Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary

Barnett S. Kramer; Karen L. Hagerty; Stewart Justman; Mark R. Somerfield; Peter C. Albertsen; William J. Blot; H. Ballentine Carter; Joseph P. Costantino; Jonathan I. Epstein; Paul Godley; Russell P. Harris; Timothy J. Wilt; Janet Wittes; Robin Zon; Paul Schellhammer

doi:10.1200/JOP.0938503

Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary

Barnett S. Kramer, Karen L. Hagerty, Stewart Justman, Mark R. Somerfield, Peter C. Albertsen, William J. Blot, H. Ballentine Carter, Joseph P. Costantino, Jonathan I. Epstein, Paul Godley, Russell P. Harris, Timothy J. Wilt, Janet Wittes, Robin Zon, Paul Schellhammer

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	127-129
Number of pages	3
Journal	Journal of Oncology Practice
Volume	5
Issue number	3
DOIs	https://doi.org/10.1200/JOP.0938503
State	Published - May 2009

Bibliographical note

Funding Information:
Collection of data included in the study was supported by the Lundbeck Foundation Center Cimbi (Grant R90-A7722).V.B.wassupportedbytheDanishCouncilforIndependentResearch–MedicalSciences(Grant4183-00627) and the Research Council of Rigshospitalet (R84-A3300). M.G. was supported by the Carlsberg Foundation (Grant 2013-01-0502)andtheNationalInstitutesofHealth(Grant5R21EB018964-02).L.F.wassupportedbytheEuropean Union’s Seventh Framework Programme (Grant FP7/2007-2013 under Agreement HEALTH-F2-2011-278850 IN-MiND).D.N.G.’sresearchwassupportedbytheNationalInstitutesofHealth(MultimodalBrainImagingofSerotonin Grant5R21EB018964-02)andtheMGHSharedInstrumentationGrantS10RR023043).WethanktheJohnandBirthe Meyer Foundation for providing the PET HRRT scanner.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1200/JOP.0938503

OpenUrl availability

Full text

Cite this

Kramer, B. S., Hagerty, K. L., Justman, S., Somerfield, M. R., Albertsen, P. C., Blot, W. J., Carter, H. B., Costantino, J. P., Epstein, J. I., Godley, P., Harris, R. P., Wilt, T. J., Wittes, J., Zon, R., & Schellhammer, P. (2009). Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary. Journal of Oncology Practice, 5(3), 127-129. https://doi.org/10.1200/JOP.0938503

Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary. / Kramer, Barnett S.; Hagerty, Karen L.; Justman, Stewart et al.
In: Journal of Oncology Practice, Vol. 5, No. 3, 05.2009, p. 127-129.

Research output: Contribution to journal › Short survey › peer-review

Kramer, BS, Hagerty, KL, Justman, S, Somerfield, MR, Albertsen, PC, Blot, WJ, Carter, HB, Costantino, JP, Epstein, JI, Godley, P, Harris, RP, Wilt, TJ, Wittes, J, Zon, R & Schellhammer, P 2009, 'Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary', Journal of Oncology Practice, vol. 5, no. 3, pp. 127-129. https://doi.org/10.1200/JOP.0938503

@article{6e729ed4c8904113815ab24020b2d239,

title = "Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary",

author = "Kramer, {Barnett S.} and Hagerty, {Karen L.} and Stewart Justman and Somerfield, {Mark R.} and Albertsen, {Peter C.} and Blot, {William J.} and Carter, {H. Ballentine} and Costantino, {Joseph P.} and Epstein, {Jonathan I.} and Paul Godley and Harris, {Russell P.} and Wilt, {Timothy J.} and Janet Wittes and Robin Zon and Paul Schellhammer",

note = "Funding Information: Collection of data included in the study was supported by the Lundbeck Foundation Center Cimbi (Grant R90-A7722).V.B.wassupportedbytheDanishCouncilforIndependentResearch–MedicalSciences(Grant4183-00627) and the Research Council of Rigshospitalet (R84-A3300). M.G. was supported by the Carlsberg Foundation (Grant 2013-01-0502)andtheNationalInstitutesofHealth(Grant5R21EB018964-02).L.F.wassupportedbytheEuropean Union{\textquoteright}s Seventh Framework Programme (Grant FP7/2007-2013 under Agreement HEALTH-F2-2011-278850 IN-MiND).D.N.G.{\textquoteright}sresearchwassupportedbytheNationalInstitutesofHealth(MultimodalBrainImagingofSerotonin Grant5R21EB018964-02)andtheMGHSharedInstrumentationGrantS10RR023043).WethanktheJohnandBirthe Meyer Foundation for providing the PET HRRT scanner.",

year = "2009",

month = may,

doi = "10.1200/JOP.0938503",

language = "English (US)",

volume = "5",

pages = "127--129",

journal = "Journal of Oncology Practice",

issn = "1554-7477",

publisher = "American Society of Clinical Oncology",

number = "3",

}

TY - JOUR

T1 - Use of 5-α-reductase inhibitors for prostate cancer chemoprevention

T2 - American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary

AU - Kramer, Barnett S.

AU - Hagerty, Karen L.

AU - Justman, Stewart

AU - Somerfield, Mark R.

AU - Albertsen, Peter C.

AU - Blot, William J.

AU - Carter, H. Ballentine

AU - Costantino, Joseph P.

AU - Epstein, Jonathan I.

AU - Godley, Paul

AU - Harris, Russell P.

AU - Wilt, Timothy J.

AU - Wittes, Janet

AU - Zon, Robin

AU - Schellhammer, Paul

N1 - Funding Information: Collection of data included in the study was supported by the Lundbeck Foundation Center Cimbi (Grant R90-A7722).V.B.wassupportedbytheDanishCouncilforIndependentResearch–MedicalSciences(Grant4183-00627) and the Research Council of Rigshospitalet (R84-A3300). M.G. was supported by the Carlsberg Foundation (Grant 2013-01-0502)andtheNationalInstitutesofHealth(Grant5R21EB018964-02).L.F.wassupportedbytheEuropean Union’s Seventh Framework Programme (Grant FP7/2007-2013 under Agreement HEALTH-F2-2011-278850 IN-MiND).D.N.G.’sresearchwassupportedbytheNationalInstitutesofHealth(MultimodalBrainImagingofSerotonin Grant5R21EB018964-02)andtheMGHSharedInstrumentationGrantS10RR023043).WethanktheJohnandBirthe Meyer Foundation for providing the PET HRRT scanner.

PY - 2009/5

Y1 - 2009/5

UR - http://www.scopus.com/inward/record.url?scp=74849099654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849099654&partnerID=8YFLogxK

U2 - 10.1200/JOP.0938503

DO - 10.1200/JOP.0938503

M3 - Short survey

AN - SCOPUS:74849099654

SN - 1554-7477

VL - 5

SP - 127

EP - 129

JO - Journal of Oncology Practice

JF - Journal of Oncology Practice

IS - 3

ER -

Use of 5-α-reductase inhibitors for prostate cancer chemoprevention: American society of clinical oncology/American Urological Association 2008 clinical practice guideline summary

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Cite this